England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for the use of GSK’s Blenrep (belantamab mafodotin) combinations to treat adults with relapsed or refractory ...

The revitalisation of GSK's blood cancer therapy Blenrep has continued with a second regulatory approval, in Japan, as a treatment for multiple myeloma. The Ministry of Health, Labour and Welfare ...

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...

(Alliance News) - GSK PLC on Monday said it has received approval in Japan for Blenrep combinations in the treatment of adults with relapsed or refractory multiple myeloma. The London-based ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

Investing.com -- GSK plc (LON: GSK), a U.K.-based pharmaceutical company, said on Monday that its Blenrep combinations have been approved by Japan’s Ministry of Health. This approval is for the ...